Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.18632/oncotarget.7924 http://scihub22266oqcxt.onion/10.18632/oncotarget.7924 C5008357!5008357!26959742     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Oncotarget 2016 ; 7 (16): 22219-33 Nephropedia Template TP {{tp|p=26959742|t=2016. Key roles of necroptotic factors in promoting tumor growth |pdf=|usr=}}{{26959742}} gab.com Text Key roles of necroptotic factors in promoting tumor growth JO: Oncotarget http://www.kidney.de/pget.php?&tw=1&pmid=26959742 #FOAvip Necroptotic factors are generally assumed to play a positive role in tumor therapy by eliminating damaged tumor cells. Here we show that, contrary to expectation, necroptotic factors RIPK1, RIPK3, and MLKL promote tumor growth. We demonstrate that genetic knockout of necroptotic genes RIPK1, RIPK3, or MLKL in cancer cells significantly attenuated their abilities to grow in an anchorage-independent manner. In addition, they exhibited significantly enhanced radiosensitivity. The knockout cells also showed greatly reduced ability to form tumors in mice. Moreover, necrosulfonamide (NSA), a previously identified chemical inhibitor of necroptosis, could significantly delay tumor growth in a xenograft model. Mechanistically, we show that necroptoic factors play a significant role in maintaining the activity of NF-?B. Finally, we found that high levels of phosphorylated MLKL in human esophageal and colon cancers are associated with poor overall survival. Taken together, we conclude that pro-necroptic factors such as RIPK1, RIPK3, and MLKL may play a role in supporting tumor growth, and MLKL may be a promising target for cancer treatment. Twit Text FOAVip Key roles of necroptotic factors in promoting tumor growth ????Oncotarget http://www.kidney.de/pget.php?&tw=1&pmid=26959742 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26959742 #FOAvip English Wikipedia <ref>{{Cite pmid|26959742}}</ref> Key roles of necroptotic factors in promoting tumor growth #MMPMID26959742 Liu X; Zhou M; Mei L; Ruan J; Hu Q; Peng J; Su H; Liao H; Liu S; Liu W; Wang H; Huang Q; Li F; Li CY Oncotarget 2016[Apr]; 7 (16): 22219-33 PMID26959742show ga Necroptotic factors are generally assumed to play a positive role in tumor therapy by eliminating damaged tumor cells. Here we show that, contrary to expectation, necroptotic factors RIPK1, RIPK3, and MLKL promote tumor growth. We demonstrate that genetic knockout of necroptotic genes RIPK1, RIPK3, or MLKL in cancer cells significantly attenuated their abilities to grow in an anchorage-independent manner. In addition, they exhibited significantly enhanced radiosensitivity. The knockout cells also showed greatly reduced ability to form tumors in mice. Moreover, necrosulfonamide (NSA), a previously identified chemical inhibitor of necroptosis, could significantly delay tumor growth in a xenograft model. Mechanistically, we show that necroptoic factors play a significant role in maintaining the activity of NF-?B. Finally, we found that high levels of phosphorylated MLKL in human esophageal and colon cancers are associated with poor overall survival. Taken together, we conclude that pro-necroptic factors such as RIPK1, RIPK3, and MLKL may play a role in supporting tumor growth, and MLKL may be a promising target for cancer treatment. äKey roles of necroptotic factors in promoting tumor growth (epmc).pdf DeepDyve Pubget Overpricing